🏛️ Verified NIH Record • Updated 2026-03-26
Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT04716452)
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Keystone Nano, Inc
🩺 Plain-English Summary (8th-Grade Level)
The study objective is to evaluate patient safety for patients with refractory and relapsed AML being treated with Ceramide NanoLiposome (CNL) .
Who can join: Review the eligibility criteria below.
Location: University of Virginia Cancer Center — Charlottesville, Virginia
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Virginia Cancer Center — Charlottesville, Virginia
📞 Contact the Study Coordinator
Phone: (814) 360-4654
Email: jadair@pendreabio.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia, in Relapse
- Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) — Gilbert, Arizona
- A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies — Charlotte, North Carolina
- Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS — Charlotte, North Carolina
- Venetoclax to Augment Epigenetic Modification and Chemotherapy — Milwaukee, Wisconsin
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) — La Jolla, California
Explore by condition: All Acute Myeloid Leukemia, in Relapse clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.